Portage Net Income vs Other Operating Expenses Analysis

PRTG Stock  USD 3.98  0.06  1.49%   
Portage Biotech financial indicator trend analysis is much more than just breaking down Portage Biotech prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Portage Biotech is a good investment. Please check the relationship between Portage Biotech Net Income and its Other Operating Expenses accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Portage Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more detail on how to invest in Portage Stock please use our How to Invest in Portage Biotech guide.

Net Income vs Other Operating Expenses

Net Income vs Other Operating Expenses Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Portage Biotech Net Income account and Other Operating Expenses. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Portage Biotech's Net Income and Other Operating Expenses is -0.36. Overlapping area represents the amount of variation of Net Income that can explain the historical movement of Other Operating Expenses in the same time period over historical financial statements of Portage Biotech, assuming nothing else is changed. The correlation between historical values of Portage Biotech's Net Income and Other Operating Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income of Portage Biotech are associated (or correlated) with its Other Operating Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Operating Expenses has no effect on the direction of Net Income i.e., Portage Biotech's Net Income and Other Operating Expenses go up and down completely randomly.

Correlation Coefficient

-0.36
Relationship DirectionNegative 
Relationship StrengthInsignificant

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Portage Biotech financial statement analysis. It represents the amount of money remaining after all of Portage Biotech operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Portage Biotech. It is also known as Portage Biotech overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.
Most indicators from Portage Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Portage Biotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Portage Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more detail on how to invest in Portage Stock please use our How to Invest in Portage Biotech guide.At this time, Portage Biotech's Issuance Of Capital Stock is most likely to increase significantly in the upcoming years. The Portage Biotech's current Enterprise Value is estimated to increase to about 365.1 M, while Selling General Administrative is projected to decrease to roughly 3.6 M.
 2021 2022 2023 2024 (projected)
Other Operating Expenses15.6M16.6M18.3M19.2M
Depreciation And Amortization15.6M1K54K51.3K

Portage Biotech fundamental ratios Correlations

0.190.330.99-0.62-0.370.130.520.980.190.31-0.140.950.190.40.57-0.070.940.96-0.11-0.29-0.20.4-0.310.690.77
0.190.930.150.240.07-0.6-0.090.23-0.260.660.590.36-0.170.64-0.03-0.090.190.260.72-0.580.090.47-0.670.260.04
0.330.930.260.150.11-0.61-0.080.38-0.320.690.480.49-0.240.720.24-0.170.350.390.62-0.510.260.39-0.60.360.15
0.990.150.26-0.67-0.410.130.550.940.330.31-0.130.930.330.40.5-0.010.870.94-0.12-0.28-0.250.39-0.330.710.71
-0.620.240.15-0.670.28-0.38-0.38-0.57-0.350.010.38-0.51-0.330.0-0.33-0.32-0.49-0.560.39-0.140.14-0.2-0.06-0.52-0.57
-0.370.070.11-0.410.280.25-0.97-0.34-0.17-0.4-0.18-0.43-0.18-0.430.26-0.28-0.26-0.45-0.040.40.15-0.010.56-0.33-0.3
0.13-0.6-0.610.13-0.380.25-0.180.110.16-0.86-0.46-0.090.12-0.850.23-0.110.2-0.01-0.470.65-0.270.030.73-0.210.31
0.52-0.09-0.080.55-0.38-0.97-0.180.50.160.390.110.560.160.44-0.040.260.420.59-0.03-0.36-0.13-0.02-0.480.420.45
0.980.230.380.94-0.57-0.340.110.50.00.31-0.140.970.00.410.61-0.080.960.98-0.11-0.3-0.140.43-0.310.620.8
0.19-0.26-0.320.33-0.35-0.170.160.160.00.0-0.140.00.99-0.04-0.110.01-0.010.02-0.170.09-0.36-0.160.010.44-0.05
0.310.660.690.310.01-0.4-0.860.390.310.00.250.490.030.96-0.010.070.230.410.29-0.770.070.17-0.830.560.07
-0.140.590.48-0.130.38-0.18-0.460.11-0.14-0.140.25-0.01-0.020.31-0.320.0-0.2-0.050.94-0.160.360.04-0.44-0.18-0.3
0.950.360.490.93-0.51-0.43-0.090.560.970.00.49-0.010.010.590.520.020.880.990.03-0.45-0.110.44-0.480.640.69
0.19-0.17-0.240.33-0.33-0.180.120.160.00.990.03-0.020.01-0.01-0.140.01-0.010.04-0.050.07-0.33-0.13-0.040.44-0.07
0.40.640.720.40.0-0.43-0.850.440.41-0.040.960.310.59-0.010.090.10.30.520.35-0.750.110.18-0.830.570.12
0.57-0.030.240.5-0.330.260.23-0.040.61-0.11-0.01-0.320.52-0.140.09-0.160.640.52-0.240.170.19-0.180.350.380.56
-0.07-0.09-0.17-0.01-0.32-0.28-0.110.26-0.080.010.070.00.020.010.1-0.16-0.250.04-0.010.01-0.220.03-0.080.250.13
0.940.190.350.87-0.49-0.260.20.420.96-0.010.23-0.20.88-0.010.30.64-0.250.88-0.15-0.22-0.130.37-0.20.60.85
0.960.260.390.94-0.56-0.45-0.010.590.980.020.41-0.050.990.040.520.520.040.88-0.04-0.4-0.130.42-0.420.620.71
-0.110.720.62-0.120.39-0.04-0.47-0.03-0.11-0.170.290.940.03-0.050.35-0.24-0.01-0.15-0.04-0.20.270.11-0.45-0.08-0.24
-0.29-0.58-0.51-0.28-0.140.40.65-0.36-0.30.09-0.77-0.16-0.450.07-0.750.170.01-0.22-0.4-0.20.26-0.330.84-0.34-0.05
-0.20.090.26-0.250.140.15-0.27-0.13-0.14-0.360.070.36-0.11-0.330.110.19-0.22-0.13-0.130.270.26-0.370.13-0.3-0.26
0.40.470.390.39-0.2-0.010.03-0.020.43-0.160.170.040.44-0.130.18-0.180.030.370.420.11-0.33-0.37-0.490.170.28
-0.31-0.67-0.6-0.33-0.060.560.73-0.48-0.310.01-0.83-0.44-0.48-0.04-0.830.35-0.08-0.2-0.42-0.450.840.13-0.49-0.39-0.04
0.690.260.360.71-0.52-0.33-0.210.420.620.440.56-0.180.640.440.570.380.250.60.62-0.08-0.34-0.30.17-0.390.65
0.770.040.150.71-0.57-0.30.310.450.8-0.050.07-0.30.69-0.070.120.560.130.850.71-0.24-0.05-0.260.28-0.040.65
Click cells to compare fundamentals

Portage Biotech Account Relationship Matchups

Portage Biotech fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets173.2M174.9M194.7M99.1M7.8M7.4M
Other Current Liab1.9M2.9M595K1.6M2.4M2.5M
Total Current Liabilities2.6M3.2M783K1.9M2.9M3.0M
Total Stockholder Equity96.5M101.4M121.2M76.0M4.0M3.8M
Net Debt509K(2.6M)(23.4M)(10.5M)(5.0M)(4.7M)
Retained Earnings(22.3M)(38.1M)(55.0M)(159.6M)(239.3M)(227.4M)
Cash3.2M2.8M23.4M10.5M5.0M3.2M
Non Current Assets Total169.4M169.9M169.8M85.5M84K79.8K
Cash And Short Term Investments3.2M2.8M23.4M10.5M5.0M6.1M
Common Stock Shares Outstanding11.0M11.7M13.1M16.1M20.3M21.4M
Liabilities And Stockholders Equity173.2M174.9M194.7M99.1M7.8M7.4M
Other Stockholder Equity58K8.0M16.9M21.2M24.4M13.3M
Total Liab27.5M27.3M29.2M23.7M4.5M6.1M
Total Current Assets3.8M4.9M24.8M13.7M7.7M7.1M
Common Stock117.8M130.6M158.3M218.8M219.5M230.5M
Short Long Term Debt Total3.7M3.7M150K47K54.1K51.3K
Non Currrent Assets Other34K58K36K877K49K46.6K
Other Assets117.4M117.4M117.4M1.01.151.09
Non Current Liabilities Total25.0M24.1M28.4M21.9M1.6M1.5M
Other Current Assets14K1.5M1.3M2.4M2.6M2.8M
Accounts Payable343K113K188K274K482K304.4K
Net Receivables60K2.2M209K682K39K37.1K
Accumulated Other Comprehensive Income32K82K958K(4.3M)23.8M25.0M
Net Tangible Assets56.4M53.2M58.1M77.9M89.6M57.7M
Long Term Investments6.4M8.6M9.1M9.1M2.9M0.0
Net Invested Capital100.2M101.6M121.2M76.0M4.0M3.8M
Net Working Capital1.2M1.7M24.0M11.8M4.8M8.8M
Capital Stock117.8M130.6M158.3M218.8M219.5M176.2M

Currently Active Assets on Macroaxis

When determining whether Portage Biotech is a strong investment it is important to analyze Portage Biotech's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Portage Biotech's future performance. For an informed investment choice regarding Portage Stock, refer to the following important reports:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Portage Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more detail on how to invest in Portage Stock please use our How to Invest in Portage Biotech guide.
You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Portage Biotech. If investors know Portage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Portage Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(70.40)
Return On Assets
(0.19)
Return On Equity
(1.91)
The market value of Portage Biotech is measured differently than its book value, which is the value of Portage that is recorded on the company's balance sheet. Investors also form their own opinion of Portage Biotech's value that differs from its market value or its book value, called intrinsic value, which is Portage Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Portage Biotech's market value can be influenced by many factors that don't directly affect Portage Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Portage Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Portage Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Portage Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.